World Coronavirus Dispatch: Concerns raised over crowded events in US

Southeast Asian technology start-ups raised less money this year as the coronavirus pandemic roiled markets, but the decline was less acute than some other parts of the world, according to a new report.

 

They raised $5.6 billion of investments in the first half of this year, down 13 per cent from a year ago, research from Singapore-based venture capital firm Cento Ventures released on Friday showed. That compares with a 16 per cent drop in India and 21 per cent fall in the EU. North America saw declines of 8 per cent during the same period, according to the report, which covered almost 3,500 deals.

 

Let’s look at the global statistics:              

 

Total Confirmed Cases: 22,413,126

 

Change Over Yesterday: 270,109

 

Total Deaths: 793,763

 

Total Recovered: 14,544,118

 

Nations hit with most cases: US (5,575,323), Brazil (3,501,975), India (2,905,825), Russia (939,833) and South Africa (599,940)

 

Source:

 

 Coronavirus cases rise in Europe, crowded events in US raise concerns: After months of decline, the coronavirus is now “steadily increasing” each week in Europe, a worrisome resurgence believed to be driven by infections among younger people, WHO said. In the US, Centers for Disease Prevention and Control expressed optimism about one region: the South. States there have begun “to turn the tide.”

 

UK retail sales rise, giving some good news to bruised sector: UK retail sales rose more than economists forecast, giving a battered sector a brief respite from a litany of bad news. Sales increased 2 per cent in July from June, according to official data. Non-food sales jumped 10 per cent, though they remain below their pre-virus level. Total volumes, including fuel, climbed above their pre-pandemic levels.

 

Also read: UK government debt tops 2 trillion pounds for first time

Alibaba reports bounce back in e-commerce: Alibaba Group’s revenue growth returned to levels not seen since the pandemic, fueling hopes of a Chinese economic recovery despite worsening US relations. China’s most valuable corporation reported better-than-expected 34 per cent sales growth in the June quarter, a shade off the 38 per cent it managed in the December quarter.

J&J plans huge vaccine study: Johnson & Johnson has confirmed that it plans to test its Covid-19 vaccine in as many as 60,000 people, twice the number of other big trials being conducted in the US. The company first posted the design for the trial on August 10, and it is set to begin in late September.

Asia-Pacific shares boosted by US tech rally: Hong Kong’s Hang Seng led the region with gains of 1.3 per cent while China’s CSI 300- and Shenzhen-listed stocks rose 0.8 per cent. Japan’s benchmark Topix index was 0.3 per cent higher. Futures markets showed US stocks on track for a slight rise at the open on Wall Street, with the S&P 500 tipped to gain 0.2 per cent.

Specials

 

Info-graphic: Latest on the vaccine development

In the race to develop weapons against Covid-19, vaccinations are key. According to WHO, 169 candidates are under development and 30 have started clinical trials. Some might be put into use as soon as this fall. Here’s an explainer about the leaders and the global stakes.

 

Why Spain is seeing a second wave

Spain's government admits the numbers are "not what we want to see", but points to key differences compared to the spring. Only around 3 per cent of current cases require hospital treatment, less than 0.5 per cent need intensive care and the current death rate is as low as 0.3 per cent. However, healthcare is a competence of Spain. Growers and packing companies have been criticised for not providing accommodation for migrant workers. Worst of all, more than 55 care homes for the elderly have registered cases since the end of the state of emergency.

Youthful Pakistan appears to avoid worst of pandemic

With a weak healthcare system, large population and many poorer families living in crowded living conditions, Pakistan seemed in danger from the outset of a catastrophic toll from coronavirus. The danger appeared to increase in June, when doctors in major cities reported that their hospitals were overwhelmed with patients. Intensive care units in the largest hospitals filled up, and families were forced to shuttle relatives around in the search for a bed. But just a few weeks later, hospital admissions appeared to fall drastically.

Cancer doctors worried about possible spikes, as people avoid care during the pandemic

While Covid-19 has upended everyone’s life, the novel coronavirus’ impact on cancer patients is especially disruptive. Any infectious disease that taxes the immune system is high on their must-avoid list—especially for those getting chemotherapy or radiation treatments, both of which can weaken natural defenses. So that leaves cancer patients caught in the middle of two terrifying diseases. Nearly 17 million people in the US are living with cancer, many of whom are currently being treated for their disease, and forced to make these difficult calculations weighing their risk of cancer against their risk of getting Covid-19.

 



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel